Common Contracts
4 similar Application and Agreement contracts
Application and Agreement for LonafarnibApplication and Agreement • October 1st, 2020
It is essential for the research community to continue investigating the effects of lonafarnib on HGPS through preclinical studies. Lonafarnib has shown some benefit to disease in Hutchinson- Gilford progeria syndrome (Gordon et al, PNAS, 2012; Gordon et al, Circulation, 2014). As new compounds emerge with potential for benefit to children with HGPS, it is also essential to perform combination drug studies using lonafarnib plus new compounds of interest. It is likely that in future, clinical trials testing new potential medications for HGPS will involve at least one combination treatment arm, administering lonafarnib plus a new drug of interest. Therefore, PRF suggests that researchers consider similar preclinical studies, with one arm testing combination treatment with lonafarnib plus new compound of interest. PRF and Eiger BioPharmaceuticals, Inc. are making lonafarnib available for these studies in order to further scientific endeavors into better treatments and cure for children wi
Application and Agreement for LonafarnibApplication and Agreement • March 6th, 2019
It is essential for the research community to continue investigating the effects of lonafarnib on HGPS through preclinical studies. Lonafarnib has shown some benefit to disease in Hutchinson- Gilford progeria syndrome (Gordon et al, PNAS, 2012; Gordon et al, Circulation, 2014). As new compounds emerge with potential for benefit to children with HGPS, it is also essential to perform combination drug studies using lonafarnib plus new compounds of interest. It is likely that in future, clinical trials testing new potential medications for HGPS will involve at least one combination treatment arm, administering lonafarnib plus a new drug of interest. Therefore, PRF suggests that researchers consider similar preclinical studies, with one arm testing combination treatment with lonafarnib plus new compound of interest. PRF and Merck are making lonafarnib available for these studies in order to further scientific endeavors into better treatments and cure for children with HGPS.
Application and Agreement for LonafarnibApplication and Agreement • March 19th, 2018
It is essential for the research community to continue investigating the effects of lonafarnib on HGPS through preclinical studies. Lonafarnib has shown some benefit to disease in Hutchinson- Gilford progeria syndrome (Gordon et al, PNAS, 2012; Gordon et al, Circulation, 2014). As new compounds emerge with potential for benefit to children with HGPS, it is also essential to perform combination drug studies using lonafarnib plus new compounds of interest. It is likely that in future, clinical trials testing new potential medications for HGPS will involve at least one combination treatment arm, administering lonafarnib plus a new drug of interest. Therefore, PRF suggests that researchers consider similar preclinical studies, with one arm testing combination treatment with lonafarnib plus new compound of interest. PRF and Merck are making lonafarnib available for these studies in order to further scientific endeavors into better treatments and cure for children with HGPS.
Application and Agreement for LonafarnibApplication and Agreement • October 25th, 2016
It is essential for the research community to continue investigating the effects of lonafarnib on HGPS through preclinical studies. Lonafarnib has shown some benefit to disease in Hutchinson- Gilford progeria syndrome (Gordon et al, PNAS, 2012; Gordon et al, Circulation, 2014). As new compounds emerge with potential for benefit to children with HGPS, it is also essential to perform combination drug studies using lonafarnib plus new compounds of interest. It is likely that in future, clinical trials testing new potential medications for HGPS will involve at least one combination treatment arm, administering lonafarnib plus a new drug of interest. Therefore, PRF suggests that researchers consider similar preclinical studies, with one arm testing combination treatment with lonafarnib plus new compound of interest. PRF and Merck are making lonafarnib available for these studies in order to further scientific endeavors into better treatments and cure for children with HGPS.
